KRAS and neoplasm: The combination of Apc and Tp53 mutations in PCs also led to an increase in tumor multiplicity upon DSS administration (1.6 fold), though to a lesser extent when compared with the compound Apc/Kras-mutant genotype, possibly indicating a distinct mechanism underlying tumor onset in these mice.